Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
AGENUS (NASDAQ: AGEN) Delayed: 3.07 +0.03 (0.99%)
Previous Close $3.04    52 Week High $7.49 
Open $2.99    52 Week Low $2.61 
Day High $3.18    P/E N/A 
Day Low $2.99    EPS $-1.10 
Volume 438,394